“Pursuing new avenues in anti-influenza therapy”

Start Date & Time: 
Friday, 1 December, 2017 - 16:00
End Date & Time: 
Friday, 1 December, 2017 - 17:00
Venue: 

Ampitheatre
Level 2
Duke-NUS Medical School
8 College Road, Singapore 169857

Speaker: 
Speaker Details: 

Dr Stephan Ludwig
Director, Institute of Virology in Muenster/Germany
Coordinator, German FluResearchNet and the National Research Platform for Zoonoses

Synopsis: 

Influenza viruses (IV) are still a major health burden worldwide. Our arsenal of antivirals is limited, not very effective and prone to resistance.

Viruses need cells to replicate. This dependence provides opportunities for a novel antiviral strategy, e.i. to target host factors instead of viral components. This concept will be illustrated on the example of the cellular Raf/MEK/ERK kinase cascade. Blockers of this cascade (a) are broadly active and inhibit IV replication in vitro and in vivo, (c) do not cause viral resistance, (d) are not toxic, and (e) display an enhanced therapeutic time window compared to standard of care.

Biography: 

Stephan Ludwig completed his PhD in virology at the University of Giessen/Germany.

From 1994 on he changed his research field to cancer research at the University of Wuerzburg. In 2002, he was appointed to a professorship for Molecular Medicine at the University of Düsseldorf.

In 2004 he moved to the University of Muenster/Germany as director of the Institute of Virology. His research interests are virus interactions with the host cell and the immune system towards development of novel antivirals. Ludwig is the coordinator of the German FluResearchNet and the National Research Platform for Zoonoses.

Host: 

Professor Gavin Smith
Programme in Emerging Infectious Diseases

and

Dr Martin Linster
Research Fellow
Programme in Emerging Infectious Diseases

 

Contact Person: 

Shirley William
shirleywilliam@duke-nus.edu.sg